News & Articles

Dr. Boye Schnack Nielsen shares tips for running successful in situ hybridization assays as he provides insights on how RNA detection methods have evolved over time

The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2

m2p-labs, BioLector family of products acquired by Beckman Coulter Life Sciences in 2020

Explore topics from micro- and nanoscale LC-MS analysis to NGS sample quality control, EEM and A-TEEM spectroscopy, and oligonucleotide analysis

Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month

Explore the latest science and technology advancements in regenerative medicine, COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction

The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods

Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences

Explore topics from live-cell analysis, in situ hybridization, cancer therapeutics, cell imaging, and much more

For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics

FDA Breakthrough Device Designation for Sepsis, Joint & Implant Infections, Infective Endocarditis, Bacterial Meningitis

In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years

Vaccine, trialed in 450 children, shows favorable safety profile and was well-tolerated

COVID-19 infections fell by 65% percent after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study

A new Prenetics Innovation Technology Centre will be established for advanced molecular diagnostics